| Based on the following information, a LifeSpan sales representative will send
you a preliminary quote or contact you for more information. For a more
accurate initial quote, please answer both the Basic and Detailed study
questions listed below. |
| Basic Study Questions: |
| 1. Goal: What is the biological question you want to answer? |
|
|
| 2. Antibodies: What antibody resources are available to your target(s)? |
|
|
| 3. Tissues: What normal and/or diseased tissues do you want screening
across (details and number of patients)? |
|
|
| 4. Timeline: When do you need the results of this study? |
|
|
| Detailed Study Questions: |
| 5. Describe the antibodies you have available for this study.(source,
clonality, isotype, immunogen, species raised in, reactivity, purification
type, humanized, conjugated (FITC, Biotin, etc), etc. |
|
|
| 6. Have you or others used the antibody in any type of assay? (IHC? FFPE?
Frozen?) If so, what were the results? |
|
|
| 7. Do you know of, or can you provide, any positive/negative human tissue
controls? (cells? xenografts?) |
|
|
| 8. If the antibody is monoclonal, do you want us to run an isotype control in
Phase I (minimum recommended) and Phase II? |
|
|
| 9. Are there specific tissue microarrays that you would like used? |
|
|
| 10. Do you need a written report of the initial antibody characterization study
against controls (Phase I) before we proceed with the test sample staining
(Phase II) or will a verbal communication suffice? |
|
|
| 11. What type of Phase II reporting do you want? |
|
|
| 12. Is there any special type of interpretation required (particular
observations, scoring, etc)? |
|
|
| 13. Is there a restricted timeline for receiving a LifeSpan quote, getting the
contract signed, and/or completing the study? |
|
|
| 14. When do you intend to initiate the study? |
|
|
| 15. Do you have any budgetary constraints we should know of before making a
proposal? |
|
|
|
A LifeSpan study quote will quickly be returned to you for consideration.
Thank You,
LifeSpan BioSciences, Inc.
|
|
|
